Quantcast
Last updated on April 19, 2014 at 9:20 EDT

LamdaGen Corporation Announces Japan Patent Issuance for Enzymatic Diagnostic Assays on Plasmonic Nano-Sensors

April 4, 2013

Patent for Ultra-Sensitive In-Vitro and POC Diagnostic Technology Platform

MENLO PARK, Calif., April 4, 2013 /PRNewswire/ – LamdaGen Corporation, a nano-technology platform company that provides plasmonic sensors and systems for diagnostics and life sciences, announced the Japanese Patent Office issuance of patent number 5203390, “Enzymatic Assays for LSPR”, which enables highly sensitive and quantitative diagnostics.

“The issuance of this patent underscores LamdaGen’s unique ability to harness the significant potential of modern plasmonics in greatly enhancing the detection sensitivity and speed of current immuno-diagnostics,” commented Randy Storer, CEO and Co-Founder of LamdaGen Corporation. “We are working with a number of companies to integrate our powerful technology into their existing diagnostic systems and devices or advanced IVD systems they have under development.”

The patent claims broadly cover nano-plasmonic surfaces and particles used in various ways as solid supports for high-speed plasmonic ELISA assays. The methods can facilitate detection limits into the femtomolar range, nearly four orders of magnitude lower than that of conventional ELISA assays.

About LamdaGen Corporation

LamdaGen is a nano-technology platform company providing plasmonic sensors and analytical systems for diagnostic and life science markets. The company’s Localized Surface Plasmon Resonance (LSPR) sensors and systems enable real-time detection of biomolecular interactions, as well as enzymatic and chemical reactions. LamdaGen is a privately held company headquartered in Menlo Park, California and is the first to offer commercial LSPR products. For more information, visit www.lamdagen.com or email info@lamdagen.com

Media Contact:
Alice F. Huang
650-571-5816
ahuang@lamdagen.com

SOURCE LamdaGen Corporation


Source: PR Newswire